H Honegger
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.
Apr 24, 2006Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Apr 24, 2006British journal of cancer 2006; 94:1099-106
Betticher D C, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny Thomas, Ris H-B, Stahel R, Spiliopoulos A, Roth A D, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK)
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Borner M, Roth A, Lanz D, Brauchli P, Honegger H, Köberle D, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8.
Feb 1, 2005A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Feb 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8
Borner M M, Roth A D, Lanz D, Brauchli P, Honegger H, Köberle Dieter, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland